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Studies in prospective cohorts have suggested that enterovirus infections are associated 
with the appearance of islet autoantibodies that precede later appearance of type 1 
diabetes (T1D). It was shown that in addition to an antibody-mediated anti-coxsackievirus 
(CV)-B neutralizing activity of serum from patients with T1D, there was also enhancing anti-
CV-B activity in vitro. In this study the patterns of enhancing and neutralizing anti-CV 
activities were analyzed from consecutive serum samples collected from children who were 
followed from birth until they developed T1D in the Finnish Type 1 Diabetes Prediction and 
Prevention (DIPP) study and compared to those in non-diabetic control children. The titers of 
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serum neutralizing activity were analyzed against those CVs which were detected in the 
stools in these children (CV-B3, CV-B5 or CV-A4) using plaque assay. The enhancing activity 
of these serum samples was analysed by measuring interferon-alpha (INF-α) production in 
cultures of peripheral blood mononuclear cells (PBMC) inoculated with a mixture of these 
viruses and diluted serum. A sustained anti-CV enhancing activity was observed in 
consecutive serum samples in patients with T1D. The pattern of responses differed between 
children who developed T1D and control children. In patients, the anti-CV enhancing activity 
was predominant or even exclusive over the neutralizing activity, whereas in controls the 
enhancing and neutralizing activities were more balanced or the neutralizing activity was 
largely predominant. In conclusion, evaluating the anti-enterovirus neutralizing and 
enhancing activity of serum samples can be useful to investigate further the relationship 
between enteroviruses and the development of T1D.  
Key-words: type 1 diabetes, enterovirus, CV-B3, CV-B5, CV-A4, IFN- α, in vitro, enhancing 
and neutralizing antibodies. 
 
Introduction 
Enteroviruses are non-enveloped positive sense single-stranded RNA viruses belonging to 
the Picornaviridae family. The Enterovirus genus encompasses thirteen species, out of which 
viruses present in certain species, namely Enterovirus A [coxsackieviruses A (CV-A) and 
enterovirus 71] and Enterovirus B [CV-A9, coxsackieviruses B (CV-B1/B6) and echoviruses] 
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are associated with acute or chronic human diseases including cardiomyopathies and type 1 
diabetes (T1D).1,2 A possible role of enteroviruses in the pathogenic process leading to T1D 
has been implicated in several studies showing an increased frequency of enterovirus 
infections and presence of enteroviruses in the pancreas of T1D patients.3 
In response to enterovirus infections, neutralizing antibodies are produced by the immune 
system. It has been shown that in addition to an antibody-mediated anti-CV-B neutralizing 
activity of serum, there is also an anti-CV-B enhancing activity of diluted serum in vitro. 
Indeed non-neutralizing antibodies have been shown to be able to enhance CV-B4 infection 
of monocytes and macrophages through interactions between the virus and cell surface 
receptors (Fc gamma RII and III and CAR) resulting in the production of IFN-α and other 
inflammatory cytokines by these cells.4,5,6 This kind of anti-CV-B enhancing activity of serum 
can worsen CV-B infection, as shown in both in vitro and in vivo mouse systems.7,8 
The enhancing activity of serum samples can be assessed by measuring the level of IFN-α  in 
the supernatants of PBMC cultures that have been inoculated with the virus mixed with 
diluted serum. Our previous studies have shown that production of IFN-α increases 
significantly when PBMC cultures are inoculated with a mixture of virus and serum from T1D 
patients when compared to PBMC cultures inoculated with the virus alone.9,10,11 These 
results suggest that the enhancing activity of serum (also called antibody-dependent 
enhancement; ADE) may contribute to the pathogenesis of T1D by increasing the severity of 
enterovirus infections. 2,12,13  Our previous studies in prospective birth cohorts have 
This article is protected by copyright. All rights reserved.
 
 
implicated that enterovirus infections are associated with the appearance of islet 
autoantibodies that precede later appearance of T1D.14,15,16,17  Hence, the current study 
aimed at evaluating the patterns of enhancing and neutralizing anti-enterovirus activities in 
consecutive serum samples collected from children who later developed T1D and to 
investigate the relationship between the antibody patterns and the development of islet 
autoantibodies and T1D. 
Materials and Methods 
Study population 
The study subjects included 12 children from the Finnish Type 1 Diabetes Prediction and 
Prevention (DIPP) study born between 1998 and 2001. The DIPP study observes, since 1994, 
infants from birth who are at risk of T1D based on their HLA DR/DQ genotypes until the age 
of 15 years or manifestation of T1D (for basic design of DIPP study, see Kupila et al., 2001).18 
Briefly, newborn infants are first screened for genetic risk of T1D HLA-DQB1 alleles and those 
with risk-associated genotypes are regularly followed for islet autoantibodies including islet 
cell autoantibodies (ICA) and autoantibodies to insulin (IAA), tyrosine phosphatase-related 
IA-2 protein (IA-2A) and glutamic acid decarboxylase 65 (GADA).  Serum samples have been 
collected every 3-12 months and stool samples monthly. 
We designed a nested case-control study to include six pairs of case-control children with 
the matching criteria including genetic susceptibility to T1D, date of birth, place of birth, and 
sex.19 The six case children had become persistently positive for multiple islet autoantibodies 
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and eventually five of them have developed T1D by the end of this study. Case and control 
children were positive for CV-B3, CV-B5, or CV-A4 in stool samples.  Case children were 
positive for CV-B3, CV-B5, or CV-A4 in stool samples before seroconversion at some point 
during their follow up period. The six control children had no detectable T1D-associated 
autoantibodies during the follow-up and were pair-wise matched with the case children.  
The DIPP study has ethical approval from the hospital districts of Southwest Finland (Turku 
University Hospital), Pirkanmaa (Tampere University Hospital), and Northern Ostrobothnia 
(Oulu University Hospital). Parents gave their informed written consent to the participation 
in the DIPP study.  
Serum and stool samples 
Serum samples have been collected at each follow-up visit performed at 3- to 12-months 
intervals and stool samples have been collected every month. Serum samples were not heat-
inactivated before assays.  The stool samples were analyzed by RT-PCR followed by 
sequencing of the viral genome for enterovirus detection and identification in stools as 
explained elsewhere.20 Type 1 diabetes-associated auto-antibodies were also detected from 








Peripheral blood mononuclear cells (PBMC) were isolated from buffy coat pellet provided by 
the French Blood Center (Lille, France). After a separation over a Ficoll-Plaque™ PLUS 
solution (GE HealthCare) by centrifugation at 500 g for 30 min at 20 °C, the PBMC fraction 
was collected and washed twice with RPMI 1640 medium (Fisher Scientific®, IllKirch, France). 
Cells were re-suspended in RPMI 1640 supplemented with 10% of fetal calf serum (FCS) 
(Fisher Scientific®) 1% of penicillin and streptomycin (Fisher Scientific®), and 1% of L-
glutamine (Fisher Scientific®). They were plated at 5x104 cells/well in 96-well tissue-culture 
plates (Fisher Scientific®). 
RD, Vero and HEp-2 cells  
Rhabdomyosarcoma cells (Human) and Vero cells (Monkey, ATCC) were grown in DMEM 
medium with 10% FCS. HEp-2 cells (BioWhittaker) were grown in Minimal essential medium 
(MEM) (Fisher Scientific®, IllKirch, France) supplemented with 10% heat-inactivated FCS, 1% 
L-glutamine, and 1% penicillin and streptomycin. This cell line was used for CV-B3 and CV-B5 
culture for virus titration. 
Viruses 
 CV-B3, CV-B5, and CV-A4 strains were obtained from ATCC and were propagated and 
titrated in HEp-2 (for CV-B3 and CV-B5) and RD cells (for CV-A4). Herpes Simplex Virus (HSV) 
1 (VR-260, ATCC®) was propagated and titrated in Vero cells. The titres of virus suspensions 
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were determined by end point dilution assay using the Reed-Muench method. Aliquots of 
virus preparations were stored at −80 °C. 
Inoculation of viruses into PBMC cultures 
The enhancing activity of serum samples was evaluated through the production of IFN-α by 
PBMCs. The virus suspensions (CV-B3, CV-B5, or CV-A4) mixed with diluted serum from DIPP 
children (1:1000) were incubated for 1 hour, followed by addition of these mixtures to PBMC 
cultures (the final Multiplicity of infection (MOI) was 5, that is 2.5 x 105 TCID50/well).   
PBMC isolated from three buffy coats were used. PBMC from one buffy coat was used for 
testing the enhancing activity of serum samples against CV-B3, from another one for testing 
the enhancing activity of serum samples against CV-B5, and from the last one for testing the 
enhancing activity of serum samples against CV-A4. Controls were (1) PBMC culture 
inoculated with either diluted serum or virus suspension (CV-B3, CV-B5 or CV-A4) alone and 
(2) PBMC culture inoculated with virus suspension mixed with diluted human control serum 
without enhancing activity. The human serum used as negative reference for enhancing 
activity assay was provided by the Department of Clinical Virology, CHU of Lille. The 
detection of neutralizing activity against CV-B3, CV-B5 and CV-A4 of this serum was negative.   
The cultures were incubated for 24h hours at 37°C in a humidified atmosphere containing 
5% CO2. At the end of the incubation period, the supernatants were harvested and stored at 
-80°C for IFNα detection by ELISA. PBMC cultures inoculated with HSV-1 served as positive 
controls of IFNα production.22 For each serum sample the enhancing activity was run in duplicate. 
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The supernatants of both wells were pooled. The level of IFN-α in the pooled supernatant was the 
mean value of determination by ELISA in duplicate.  
 
IFN-α 
The level of IFNα obtained in the supernatants were determined using the IFNα pan-specific 
ELISA kit (Mabtech®, Sophia Antipolis, France) that allows the detection of IFN-α subtypes 
1/13, 2, 7, 8, 16, and 17. The manufacturer's guidelines were strictly followed for the assay 
and the detection range was 7-700 pg/mL. 
Neutralizing activity assay 
The virus seroneutralization assay was used to determine the titers of neutralizing activity of 
serum samples against the virus detected in the stools of children. A standard plaque 
reduction assay detected neutralizing antisera. Serial dilutions of sera were incubated with 
approximately 100 PFU of infectious virus for 1 h at 37°C, continued overnight at room 
temperature. Neutralizing reactions were then added to 95% confluent GMK cells in 12 well 
plates (Nunc). After 1 h incubation at 37°C to let virus attach to cellular receptors, a 
semi-solid media (MEM supplemented with 0.67% carboxymethyl cellulose) was added to 
cell monolayer and plates were incubated for 2 days at 37°C in a humid chamber with 5% 
CO2. Assay was developed by fixing the cells with formaldehyde solution (4%) containing 
crystal violet to visualize the plaques. The mean number of plaques in 3 control wells was 
determined. A reduction in plaque number ≥80% in test well compared with untreated virus 
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suspension was considered positive. If the number of plaques was  between  the cutoff value +/-2 
plaques , the assay was repeated to ensure the accuracy of the results 17.  
 
Statistical analysis 
The statistical analyses were performed using the GraphPad Prism® V6.0 software. 




Pattern of neutralizing and enhancing anti-enterovirus activities of serum from children 
Nine consecutive serum samples were collected from the child #c1 along a follow-up period 
for 100-months. CV-B3 was identified in a stool sample obtained from this individual at the 
age of 13 months. An anti-CV-B3 neutralizing activity of serum peaked after the detection of 
CV-B3 in stools remaining elevated during later follow-up (titre value up to 2048 on month 
99) (Fig. 1A c1).  Relatively high enhancing activity was detected in four follow-up serum 
samples (IFN-α levels ranged from 168 to 863 pg/mL) whereas in other samples the values 
were lower (25 to 87 pg/mL) (Fig.1A c1).   
CV-B5 was identified in stools at the age of 27 months in child #b whose eight consecutive 
serum samples were collected along a follow-up period for 62-months. Anti-CV-B5 
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neutralizing activity peaked after the infection (ranging from 4 to 256) but a moderate 
enhancing activity (with a maximum IFN-α value of 144 pg/mL (Fig. 1A c2) was seen already 
before the infection. 
CV-A4 was identified in a stool sample obtained from the four remaining children (#c3 - c6) 
whose 5 to 9 consecutive serum samples were collected along follow-up periods stretching 
over 24 to 60 months (Fig. 1A c3 - c6). An anti-CV-A4 neutralizing activity (titre values up to 
512) increased in serum samples collected after the CV-A4 infection. There was no 
neutralizing activity in serum samples collected prior to virus identification in three of these 
children. However, high anti-CV-A4 neutralizing activity (titre value 512) was observed in a 
serum sample collected already at the age of one month from one of these children (#c3) 
(Fig. 1A c3).  This child was CV-A4 positive in the stool sample collected at the age of 10 
months (Fig. 1A c3).  The neutralizing activity of every serum sample was associated with an 
enhancing activity (2 to 2000 pg/ml IFN-α).  
 
Pattern of neutralizing and enhancing anti-enterovirus activities of serum from children 
with T1D and/or with T1D auto-antibodies 
The pattern of serum neutralizing and enhancing anti-enterovirus (CV-B3, CV-B4, or CV-B5) 
activities was studied in the six patients and matched controls who all were positive for CV-
B3, CV-B5, or CV-A4 in stools (Fig. 1B). Larger inter-individual variations was seen in both 
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neutralizing and enhancing antibody titres in patients (#a1 - a6) compared to controls (Fig. 
1B a1 – a6). 
There was no neutralizing activity in serum samples collected prior to virus detection in 
stools except in two individuals.  An anti-CV-B5 neutralizing activity of serum (titre value 
1024) was found one month prior to the detection of CV-B5 in stools (on month 13) in one 
patient (#a2) (see Fig. 1B a2). An anti-CV-A4 neutralizing activity, but at a lower level (titre 
value 4), was observed in month 18 about one month prior to the detection of CV-A4 in 
stools in another case child (#a3) (see Fig. 1B a3). Otherwise, a neutralizing serum activity 
was seen only in samples obtained after the detection of an enterovirus in the stool sample. 
In the patient with CVB3 in the stool sample (#a1) (Fig. 1 Ba1), the rate of anti-CV-B3 
neutralizing activity of serum fluctuated substantially over time (up to 1024 in month 19, 
then as low as 16 in month 26 and 36 and then up to 1024 in month 48). A major difference 
between the patients and controls was the predominance of the enhancing serum activity 
compared with the neutralizing activity (see Fig. 1B). A predominant enhancing activity was 
observed in most of the consecutive samples obtained from the patient with CV-B3 (#a1), as 
well as the patient with CVB5 (#a2) along with three out of four patients with CV-A4 (#a3 – 
a6) (Fig. 1 Ba1 – a6). However, one of the patients with CV-A4 positivity in stools (#a6) had 
low enhancing antibody activity (15 pg/mL) (Fig. 1B a6). This child had also low neutralizing 
activity. A predominant anti-CV-A4 enhancing activity was seen in one (in month 26) of his 
four consecutive samples collected over a follow up period for 16-months following virus 
identification in the stool sample (Fig. 1 B a6).  
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T1D-associated autoantibodies were present in the serum sample of each patient following 
the identification of CVB5 or CV-A4 in the stools sample: (1) ICA and GADA in three patients 
with CV-A4 (#a3 #a5 and #a6) (Fig. 1 Caa2 and Fig. 1 Caa3, aa5 and aa6), (2) ICA, GADA, and 
IA2 in the other patient with CV-A4  (#a4) as well as in the patient with CVB5 (#a2) (fig. 1 
Caa4 and fig. 1 Caa2). The presence of autoantibodies in the serum sample was associated 
with an anti-enterovirus activity that was mainly enhancing activity.  The sera taken prior to 
autoantibody appearance had no enhancing/neutralizing activity against the enteroviruses 
identified in stools in four out of the six patients whereas an anti-CV-A4 activity of serum 
samples was detected prior to the identification of CV-A4 in the stools sample in one patient 
(#a5) (see Fig. 1 Ba5 and Fig. 1 Caa5). T1D autoantibodies (ICA) and anti-CV-B3 enhancing 
activity were present in the serum sample of a patient (#a1) with CV-B3 in the stool sample 
along time (57 months) prior to the appearance of autoantibodies (see Fig 1 Ba1 and Fig. 1 
Caa1). During this period, an anti-CV-B3 activity was detected in two out of eight serum 
samples.  
Five out of six individuals with T1D autoantibodies in their serum developed clinical disease. 
These patients had a predominant enhancing anti-enterovirus activity in consecutive serum 
samples collected prior to the presentation of T1D. An anti-CV-B5 predominant enhancing 
activity in five consecutive serum samples through month 20 to 32 was observed in the 
patient #a2 who developed the disease on month 43 (Fig. 1 Ba2). An anti-CV-A4 
predominant enhancing activity in four consecutive serum samples collected through 
months 24 to 65 was observed in a patient (#a3) who presented with T1D in month 87, as 
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presented graphically (Fig. 1 Ba3). An anti-CV-A4 predominant enhancing activity was also 
seen in seven consecutive serum samples collected through months 23 to 62 and in five 
consecutive serum samples collected through months 22 to 60 in two patients (#a4 and #a5) 
who presented with T1D in month 62 and 60 respectively (Fig 1 Ba4 and Ba5). However, an 
anti-CV-A4 predominant enhancing activity at a lower titre was observed in one out of three 
consecutive samples (collected through month 19 to 29) in one patient (#a6) who was 
diagnosed with T1D in month 29 (Fig. 1 Ba6).  
The different patterns of values of neutralizing activity and of enhancing activity obtained 
from serum collected after identification of virus in stool samples have been studied (see 
figure 2). The mean level of enhancing activity was higher in patient #a3 than in matched 
control #c3 (p < 0.05). The mean level of neutralizing activity in patient #a5 was lower than 
in controls #c5 (p < 0.05). The levels of neutralizing and enhancing activities were lower in 
patient #a6 than in control #c6 and  an  enhancing activity  against CV-A4  was found in only 
one serum sample of the patient #a6 (p < 0.05) (see figure 2 A and B). The ratio of enhancing 
and neutralizing activity values in each serum sample was calculated followed by the mean 
calculation of ratio values for each individual. The mean of these values obtained with serum 
samples of patients was higher than the one obtained with serum samples of matched 
controls (18.01 +/-15.16 vs 2.99 +/- 2.76 p < 0.05) (figure 2 C).  
 
Discussion   
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In many respects the current study is different from previous studies carried out to evaluate 
the possible role of enhancing antibodies in T1D. Most importantly, this is the first 
prospective study where neutralizing and enhancing anti-enterovirus activities were 
analyzed from consecutive serum samples collected from children prior to the diagnosis of 
T1D and covering time periods before and after enterovirus infections that were diagnosed 
by detecting the virus in stool samples.   
Several considerations are noteworthy. The serum samples were obtained from children 
followed from birth in the Finnish T1D Prediction and Prevention (DIPP) study covering 
different stages of the beta-cell damaging process including the start of islet autoimmunity 
(appearance of islet autoantibodies). Both case and control children carried HLA risk genes 
for T1D and were additionally carefully matched for possible other confounding factors 
including date of birth, sex and geographic region.   Such prospective collection of biological 
samples and data is the most suitable and powerful approach for analyzing and evaluating 
the relationship between factors associated with a disease. The available volume of stored 
serum samples from such individuals is usually limited; especially from infants. A small 
volume of serum was required to investigate the neutralizing activity and for testing the 
enhancing activity against the identified serotypes (9 µL and 12 µL respectively). In order to 
analyze the intra-individual variations of serum activity, the same batch of buffy coat derived 
PBMCs was used for testing serum samples from the control and paired patient, and all the 
consecutive serum samples for case-control pairs were tested in the same run.   
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In our previous studies anti-CV-B4 and anti-CV-B3 enhancing activity was analyzed from 
serum samples collected from controls and patients with established T1D.9,10,11    In the 
present study, we found that serum enhancing activity against CV-B5 and CV-A4 in vitro was 
elevated already prior to the diagnosis of T1D, as case children had a higher IFN-α response 
to virus-serum mixture compared to control children.  
For the first time, we were able to standardize this case-control comparison by analyzing 
enhancing activity before and after the infection in case and control children who were 
infected by the same enterovirus types. The virus was not isolated from the stools samples 
of the individuals, but the identification of the genotype by nucleotide sequencing opened 
the possibility to study the activity of serum against the relevant serotype of ATCC reference 
strains.  
The neutralization assay provides a reflection of the activity of biological samples due to 
neutralizing antibodies against the challenging virus.23,24 A neutralizing activity is observed 
soon after the infection and the responses are usually long-lasting and serotype-specific. This 
was also seen in the current study. However, in some children the neutralizing antibodies 
were detected prior to virus detection in stool sample, which is most likely explained by long 
shedding of the virus into stools and lack of any stool sample that would have been collected 
in the acute phase of the viral disease (stool samples were collected according to a 
predetermined monthly schedule). 
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Thus, it can be assumed that the observed neutralizing activity is relevant and is induced by 
the serotype identified in the stool samples. Nevertheless, this activity may be the result of 
reactivation of the immune response to the infection as suggested by the detection of a 
neutralizing activity of a serum sample collected 10 months prior to the serotype 
identification in the stool samples of two control subjects (one was CV-B3 positive and the 
other  CV-A4 positive). Furthermore, it cannot be excluded that in these individuals the 
neutralizing serum activity observed prior to the serotype identification was due to 
heterotypic reactions in response to infections with other unidentified serotypes25. 
As far as individuals with CV-A4 infections were concerned, there was an anti-CV-A4 
enhancing activity of serum samples collected 10 months prior to the presence of this 
serotype in the stool samples whereas there was no neutralizing activity against this virus in 
these samples (see fig 1A c4). It is possible that this is due to cross-reacting non-neutralizing 
enhancing antibodies. However, in previous studies we found that enhancing antibodies 
were not cross-reactive between serotypes but rather induced by the homotypic virus. 10 
Furthermore, the neutralizing and /or enhancing activities of serum samples obtained a few 
months after birth (3 months) before the detection of virus in stools, as observed in some 
individuals (controls # c1 – c4 and patient #a5), can be due to maternal antibodies. 
The enhancing activity of serum samples from patients obtained after the detection of virus 
in stools was predominant except in the case of patient #a6. The pattern of values of 
neutralizing and enhancing activities of serum samples from this patient was different 
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compared to those of other patients. An anti-CV-A4 enhancing activity was observed in one 
serum sample only. The discrepancy between the pattern of results obtained with serum 
samples from this patient and those of others may be explained by the fact that CV-A4 was 
possibly not the relevant virus as far as this patient is concerned.   
Whether the sustained anti-enterovirus enhancing activity of consecutive serum samples in 
patients with T1D auto-antibodies reflects a disturbance of the immune system or an odd 
response to enteroviruses is an open question26. The fact that the serum samples from 
patients mixed with enteroviruses enhanced the virus-induced production of IFN-α by 
PBMCs in vitro is in line with previous studies suggesting that IFN-α may play a role in 
pathogenesis of T1D.2,27,28 Whether the anti-enterovirus enhancing activity observed in at 
risk subjects or in patients with T1D can be involved in the development of autoimmunity 
should be explored further. 
In conclusion, the anti-enterovirus neutralizing and enhancing activity of consecutive serum 
samples from controls and patients were investigated in this proof-of-concept study. The 
number of patients was limited, but the results indicated that the pattern of response to 
enteroviruses is different in individuals who develop T1D compared to controls. The 
determination of the pattern of response to enteroviruses as described here could be 
implemented in future studies based on larger cohorts of patients, at risk individuals and 
control subjects. Bioassays aimed at evaluating the anti-enterovirus neutralizing and 
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enhancing activity of serum samples can be useful to investigate further the relationship 
between enteroviruses and T1D. 
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Legend of figure 1: Neutralizing and enhancing anti-coxsackievirus activities of serum 
samples obtained from controls and from patients prior to the onset of type 1 diabetes. 
Consecutive serum samples were obtained from six patients and six matched controls during 
a follow-up period ranging from birth to the age of 27 to 99 months (x-axis). Neutralizing 
(black bars) and enhancing (white bars) activities of serum samples are shown for controls 
(A) and patients (B) against a relevant reference strain of coxsackievirus types that was 
found in stools of these children by RT-PCR and identified by nucleotide sequencing. The 
date of sample positive for the detection of virus in stools is indicated by vertical arrows and 
the type of virus is indicated (CVB3, CVB5 or CVA4).   The pattern of T1D-associated 
autoantibodies (ICA, IAA, IA-2A and GADA) in each patient during the follow-up is shown (C). 
The date of diagnosis of T1D is marked in the graphs of panel B. In the patient #a3 
represented by graph Ba3 T1D was diagnosed at the age of 87 months as marked on the 
right side of the graph.  
Legend of figure 2: Neutralizing and enhancing anti-coxsackievirus activities of serum 
samples obtained from controls and from patients after the detection of viruses in stools. 
Neutralizing (A) and enhancing (B) anti-coxsackievirus activities of consecutive serum 
samples obtained from six patients (#a1-a6) and six matched controls (#c1-c6) after 
detection of viruses in stools.  The geometric means and the error bars representing the 
lower and upper 95% CI (A) and the arithmetic means +/- SD (B) are shown. The ratio of 
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enhancing and neutralizing activity values in each serum sample obtained from the six  
patients (#a1-a6) and from the six controls (#c1-c6) was calculated followed by the mean 
calculation of ratio values for each individual, the mean value for a  patient and matched 
control are represented  by the same symbol (C).  * p value < 0.05. 
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